Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculation

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue , 2013, Pages 149-150

  Pickett, Andy ^a,b  

^a Toxin Science Limited   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

CLINICAL PRACTICE; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG NOMENCLATURE; DRUG PACKAGING; DRUG STORAGE; ESTHETICS; LETTER;

EID: 84884376362     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S47086     Document Type: Letter

References (6)

1. Prager W. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clin Pharmacol. 2013;5:39-52.
2. Pickett A. Immunogenicity issues related to botulinum toxins in clinical use cannot be answered by speculation about product characteristics. BioDrugs. 2013;27(1):83-84.
3. Eisele K-H, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4):555-565.
4. Prager W, Huber-Vorlander J, Taufig AZ, et al. Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice. Clin Cosmet Investig Dermatol. 2012;5:53-58.
5. Pickett A, Caird D. Comparison of type a botulinum toxin products in clinical use. J Clin Pharm Ther. 2008;33(3):327-328.
6. Pickett A. Inability of speculation to explain dose effect differences between botulinum toxin products. Arch Facial Plast Surg. 2012;14(6): 467-468.